BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
Executive Summary
The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins
You may also be interested in...
FDA “Follow-On” Biologics Framework Development Will Become More Public
FDA's development of a framework for "follow-on" biologics will become a more public process after the agency resolves internal questions about scientific issues, Office of New Drugs Deputy Director Sandra Kweder, MD, said April 16
FDA “Follow-On” Biologics Framework Development Will Become More Public
FDA's development of a framework for "follow-on" biologics will become a more public process after the agency resolves internal questions about scientific issues, Office of New Drugs Deputy Director Sandra Kweder, MD, said April 16
FDA Generic Biologics “Structure” To Come Soon; Policy Debate In 2005
FDA hopes to be in a position to kick off a legislative and policy debate on the feasibility of "follow-on" biologics by the beginning of 2005